Novacap and all its activities and subsidiaries (Novacarb, Novacyl, Novapex, Novacid, Novabay, Uetikon, H2B, ID Bio, PCAS, Chemoxy and PCI Synthesis) unify their names into a new one and become Seqens. Specialising in pharmaceutical synthesis and specialty ingredients for the healthcare, electronic, cosmetic, food and homecare markets, the group operates 24 manufacturing plants and three R&D centres in Europe, North America and Asia with 3,200 employees.
Seqens refers naturally to the group core synthesis activities, mixed with that sequencing idea.
“As Seqens, we intend to stand as a strong, global and integrated player in pharmaceutical synthesis and specialty ingredients. Our mission is to bring R&D and industrial performance to our clients’ projects. From now on, we want to better leverage on our strong expertise to develop and produce highly complex molecules with unique skills and the largest continuum of technologies available on the market. I am proud of what we have achieved so far, on behalf of Seqens’ 3,200 scientists, engineers, and experts working across a range of fields such as QHSE, industrial methods and processes, quality, sales and marketing, finance, innovation, legal and more,” says Pierre Luzeau, Seqens CEO.
